StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Regenxbio's enterprise value was $353.27M on Nov 11, 2026, against $375.79M a year earlier. Over the last 5 years it ranged from $80.64M to $864.49M, with a median of $302.35M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$353.27M-17.3%
2025Dec 31, 2025$426.91M+309.3%
2024Dec 31, 2024$104.30M-75.5%
2023Dec 29, 2023$425.14M+16.5%
2022Dec 30, 2022$364.86M-57.8%
2021Dec 31, 2021$864.49M-38.6%
2020Dec 31, 2020$1.41B+28.8%
2019Dec 31, 2019$1.09B+6.8%
2018Dec 31, 2018$1.02B+21.3%
2017Dec 29, 2017$843.27M+175.4%
2016Dec 30, 2016$306.25M+37.1%
2015Dec 31, 2015$223.33M–

More Regenxbio figures

See a number that looks wrong?